IBDEI1U8 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32367,0)
 ;;=E11.21^^182^1984^15
 ;;^UTILITY(U,$J,358.3,32367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32367,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,32367,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,32367,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,32368,0)
 ;;=E11.39^^182^1984^16
 ;;^UTILITY(U,$J,358.3,32368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32368,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,32368,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,32368,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,32369,0)
 ;;=E11.43^^182^1984^14
 ;;^UTILITY(U,$J,358.3,32369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32369,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,32369,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,32369,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,32370,0)
 ;;=E11.59^^182^1984^12
 ;;^UTILITY(U,$J,358.3,32370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32370,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,32370,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,32370,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,32371,0)
 ;;=E11.618^^182^1984^13
 ;;^UTILITY(U,$J,358.3,32371,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32371,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,32371,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,32371,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,32372,0)
 ;;=E11.621^^182^1984^17
 ;;^UTILITY(U,$J,358.3,32372,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32372,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,32372,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,32372,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,32373,0)
 ;;=E11.622^^182^1984^19
 ;;^UTILITY(U,$J,358.3,32373,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32373,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,32373,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,32373,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,32374,0)
 ;;=E11.65^^182^1984^18
 ;;^UTILITY(U,$J,358.3,32374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32374,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,32374,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,32374,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,32375,0)
 ;;=E11.9^^182^1984^20
 ;;^UTILITY(U,$J,358.3,32375,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32375,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,32375,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,32375,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,32376,0)
 ;;=E13.9^^182^1984^21
 ;;^UTILITY(U,$J,358.3,32376,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32376,1,3,0)
 ;;=3^Diabetes Mellitus w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,32376,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,32376,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,32377,0)
 ;;=E16.2^^182^1984^28
 ;;^UTILITY(U,$J,358.3,32377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32377,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,32377,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,32377,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,32378,0)
 ;;=E20.0^^182^1984^33
 ;;^UTILITY(U,$J,358.3,32378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32378,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,32378,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,32378,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,32379,0)
 ;;=E20.9^^182^1984^29
 ;;^UTILITY(U,$J,358.3,32379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32379,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,32379,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,32379,2)
 ;;=^5002714
 ;;
 ;;$END ROU IBDEI1U8
